144 related articles for article (PubMed ID: 15494261)
1. Electrolyte disturbances may predispose nucleoside analogue-treated AIDS patients to acute renal failure.
Spichler AS; Seguro AC
Int J Infect Dis; 2004 Nov; 8(6):377-8. PubMed ID: 15494261
[No Abstract] [Full Text] [Related]
2. Nucleoside analogues in 2008.
Warwick Z; Churchill D
J HIV Ther; 2008 Mar; 13(1):3-8. PubMed ID: 18953267
[No Abstract] [Full Text] [Related]
3. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
Psevdos G; Gonzalez E; Sharp V
AIDS Read; 2009; 19(6):245-8. PubMed ID: 19642243
[TBL] [Abstract][Full Text] [Related]
4. Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects.
Bongiovanni M; Fausto A; Cicconi P; Aliprandi A; Cornalba G; Bini T; Sardanelli F; D'Arminio Monforte A
J Antimicrob Chemother; 2006 Aug; 58(2):485-6. PubMed ID: 16751202
[No Abstract] [Full Text] [Related]
5. Nucleoside analogues toxicities related to mitochondrial dysfunction: focus on HIV-infected children.
Viganò A; Giacomet V
Antivir Ther; 2005; 10 Suppl 2():M53-64. PubMed ID: 16152706
[No Abstract] [Full Text] [Related]
6. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
Songa PM; Castelnuovo B; Mugasha EB; Ocama P; Kambugu A
Clin Infect Dis; 2007 Aug; 45(4):514-7. PubMed ID: 17638205
[TBL] [Abstract][Full Text] [Related]
7. Side effects and combination anti-HIV drugs.
Treat Rev; 1997 Nov; (No 26-27):14-5. PubMed ID: 11364933
[TBL] [Abstract][Full Text] [Related]
8. [Drug clinics. How I treat HIV infections. II. Nucleoside reverse transcriptase inhibitors].
Moutschen M; Nkoghe D; Léonard P; Demonty J
Rev Med Liege; 1997 Dec; 52(12):750-2. PubMed ID: 9481171
[No Abstract] [Full Text] [Related]
9. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
10. [Nucleoside reverse transcriptase inhibitors. Sex-specific effectiveness and tolerance].
MMW Fortschr Med; 2000 Mar; 142 Suppl 1():42-3. PubMed ID: 10863310
[No Abstract] [Full Text] [Related]
11. Symptomatic hyperlactatemia in a patient on nucleoside reverse transcriptase inhibitors.
Ball SC
AIDS Read; 2001 Dec; 11(12):593-5. PubMed ID: 11806170
[No Abstract] [Full Text] [Related]
12. Decrease of mitochondrial DNA level in sperm from patients infected with human immunodeficiency virus-1 linked to nucleoside analogue reverse transcriptase inhibitors.
Pavili L; Daudin M; Moinard N; Walschaerts M; Cuzin L; Massip P; Pasquier C; Bujan L
Fertil Steril; 2010 Nov; 94(6):2151-6. PubMed ID: 20153854
[TBL] [Abstract][Full Text] [Related]
13. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
[TBL] [Abstract][Full Text] [Related]
14. Nucleoside reverse-transcriptase inhibitor use, cirrhosis, and end-stage liver disease in HIV-infected patients.
Remtulla RA; Decker CF
Clin Infect Dis; 2008 Nov; 47(9):1233-4; author reply 1234. PubMed ID: 18831698
[No Abstract] [Full Text] [Related]
15. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
Gallant JE; Parish MA; Keruly JC; Moore RD
Clin Infect Dis; 2005 Apr; 40(8):1194-8. PubMed ID: 15791522
[TBL] [Abstract][Full Text] [Related]
16. Editorial comment: mixing tenofovir with other nephrotoxins--how safe is this?
Gupta SK
AIDS Read; 2009; 19(6):246. PubMed ID: 19642244
[No Abstract] [Full Text] [Related]
17. HIV-associated antiretroviral toxic neuropathy (ATN): a review of recent advances in pathophysiology and treatment.
Youle M
Antivir Ther; 2005; 10 Suppl 2():M125-9. PubMed ID: 16152714
[No Abstract] [Full Text] [Related]
18. Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors.
Brinkman K
Clin Infect Dis; 2000 Jul; 31(1):167-9. PubMed ID: 10913416
[No Abstract] [Full Text] [Related]
19. Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy.
Calza L; Manfredi R; Chiodo F
Clin Nutr; 2005 Feb; 24(1):5-15. PubMed ID: 15681097
[TBL] [Abstract][Full Text] [Related]
20. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens.
Lonergan JT; Behling C; Pfander H; Hassanein TI; Mathews WC
Clin Infect Dis; 2000 Jul; 31(1):162-6. PubMed ID: 10913415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
